Renovaro Biosciences Updates Contact Info, Confirms Name

TL;DR

**Renovaro Biosciences filed an 8-K updating its phone number and confirming its current name.**

AI Summary

Renovaro Biosciences Inc. filed an 8-K on January 25, 2024, primarily to update its contact information, specifically changing its business phone number to +1 (305) 918-1980. This filing also confirms the company's current name after several changes, including Enochian Biosciences Inc. and Renovaro Biosciences Inc. (again), with the latest name change occurring on August 4, 2023. For investors, this matters because it provides updated contact details and confirms the company's current legal identity, which is crucial for due diligence and communication.

Why It Matters

This filing provides updated contact information for Renovaro Biosciences Inc., which is important for investors needing to reach the company. It also clarifies the company's current legal name after a series of recent changes, ensuring investors have accurate identification.

Risk Assessment

Risk Level: low — This filing is administrative, updating contact information and confirming the company's name, which carries minimal direct risk.

Analyst Insight

A smart investor would note the updated contact information and confirm the company's current legal name for their records, but this filing alone does not suggest any immediate investment action.

Key Numbers

• +1 (305) 918-1980 — New Business Phone Number (The updated contact number for Renovaro Biosciences Inc.)

Key Players & Entities

• RENOVARO BIOSCIENCES INC. (company) — the registrant filing the 8-K
• +1 (305) 918-1980 (dollar_amount) — new business phone number
• January 25, 2024 (person) — date of earliest event reported
• Enochian Biosciences Inc. (company) — former company name
• August 4, 2023 (person) — date of latest name change

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar

Filing Documents

• e5384_8-k.htm (8-K) — 39KB
• e5384_ex99-1.htm (EX-99.1) — 3KB
• 0001731122-24-000159.txt ( ) — 214KB
• renb-20240125.xsd (EX-101.SCH) — 3KB
• renb-20240125_lab.xml (EX-101.LAB) — 33KB
• renb-20240125_pre.xml (EX-101.PRE) — 22KB
• e5384_8-k_htm.xml (XML) — 3KB

07. Submission

Item 5.07. Submission of Matters to a Vote of Security Holders. On January 25, 2024, Renovaro Biosciences Inc., a Delaware corporation ("Renovaro"), held its special meeting stockholders (the "Meeting") as described in the definitive proxy statement filed by Renovaro with the Securities and Exchange Commission on January 3, 2024, as amended and supplemented from time to time (the "Proxy Statement"). As disclosed in the Proxy Statement, as of the close of business on December 29, 2023, the record date for the Meeting, there were 67,224,089 shares of common stock, par value $0.0001 per share, of Renovaro ("Common Stock") outstanding and entitled to vote at the Meeting and 561,010 shares of Series A Convertible Preferred Stock, par value $0.0001 per share, of Renovaro ("Series A Preferred Stock") outstanding and entitled to vote at the Meeting, such shares of Series A Preferred Stock collectively representing 5,610,100 votes entitled to be cast at the Meeting. A total of 33,588,000 votes, representing approximately 46.12% of the voting power of Renovaro's capital stock outstanding and entitled to vote at the Meeting and constituting a quorum, were represented in person or by proxy at the Meeting. The final voting results for each of the proposals submitted to a vote of the Renovaro stockholders at the Meeting are as follows: Proposal No. 1 : Approval, for purposes of Listing Rule 5635 of The Nasdaq Stock Market LLC ("Nasdasq"), of the issuance of shares of Common Stock , pursuant to the Stock Purchase Agreement, dated September 28, 2023 (the "Stock Purchase Agreement"), by and among GEDi Cube Intl Ltd., the sellers party thereto, and Yalla Yalla Ltd., in its capacity as the representative of such sellers, which approval is necessary to consummate the transactions contemplated by the Stock Purchase Agreement. The stockholders approved this proposal as follows: Votes For 32,181,201 Votes Against 10,324 Abstentions 1,997 Broker Non-Votes 1,394,478 Propos

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO BIOSCIENCES INC. By: /s/ Luisa Puche Name: Luisa Puche Title: Chief Financial Officer Date: January 25, 2024

View Full Filing

View this 8-K filing on SEC EDGAR